Hanfei Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hanfei Wu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Junjun Cao
Nanjing LivingChip Biotechnology Co., Ltd Nanjing China
2 shared publicationsQuan Liu
Department of Otolaryngology Eye, Ear, Nose and Throat Hospital Fudan University Shanghai China
2 shared publicationsYan Mei
Nanjing LivingChip Biotechnology Co., Ltd Nanjing China
2 shared publicationsYong Qiao
Nanjing LivingChip Biotechnology Co., Ltd Nanjing China
2 shared publicationsChuanqian Yi
School of Nano‐Tech and Nano‐Bionics University of Science and Technology of China Hefei Anhui China
1 shared publicationDanyue Zhi
School of Nano‐Tech and Nano‐Bionics University of Science and Technology of China Hefei Anhui China
1 shared publication
Latest Publications
- Open Access
Bispecific NK‐Cell Engager Targeting TP53 Mutation Through Integration of a TCR‐mimic Antibody
Natural killer (NK) cells are valuable for cancer immunotherapy because they kill tumor cells without prior sensitization or human leukocyte antigen (HLA) restriction. However, their efficacy is often limited by immune‐evasion, especially major histocompatibility complex I (MHC‐I)‐mediated NK cell inhibition. NK cell engagers (NKCEs) can redirect NK cells to tumor for more effective immunotherapy, but most current NKCEs target tumor‐associated antigens (TAAs), risking on‐target, off‐tumor toxicity in clinical applications. Neoantigens, as tumor‐specific antigens (TSAs) arising from somatic mutations and presented by MHC‐I on tumor cell surfaces, represent ideal tumor‐specific target. Here, we engineered NKCEs built on neoantigen‐targeting TCR‐mimic antibodies (TCRm‐Abs) to enhance tumor‐specific NK cell‐mediated cytotoxicity. Using a high‐throughput hydrogel‐based microwell single‐cell chip (HMSC‐chip) coupled with T2 cell‐based de‐selection, we identified C33‐Ab, a functional TCRm‐Ab specific for p53 R175H /HLA‐A*02:01, from ∼500,000 hybridoma cells within 8 weeks. Based on this TCRm‐Ab, we constructed a bispecific NKCE (C33×CD16), a single‐chain diabody (scDb) linking C33‐Ab to an anti‐CD16 scFv. C33×CD16 specifically bridges NK cells with p53 R175H /HLA‐A*02:01‐positive cancer cells. It potently enhanced NK cell‐mediated cytotoxicity in vitro and antitumor efficacy in vivo upon adoptive NK‐cell transfer. This TCRm‐Ab‐based bispecific NKCE offers a promising strategy for tumor‐specific NK cell‐mediated immunotherapy by targeting intracellular oncogenic hotspot mutations.
Open AccessBispecific NK‐Cell Engager Targeting TP53 Mutation Through Integration of a TCR‐mimic Antibody
Natural killer (NK) cells are valuable for cancer immunotherapy because they kill tumor cells without prior sensitization or human leukocyte antigen (HLA) restriction. However, their efficacy is often limited by immune‐evasion, especially major histocompatibility complex I (MHC‐I)‐mediated NK cell inhibition. NK cell engagers (NKCEs) can redirect NK cells to tumor for more effective immunotherapy, but most current NKCEs target tumor‐associated antigens (TAAs), risking on‐target, off‐tumor toxicity in clinical applications. Neoantigens, as tumor‐specific antigens (TSAs) arising from somatic mutations and presented by MHC‐I on tumor cell surfaces, represent ideal tumor‐specific target. Here, we engineered NKCEs built on neoantigen‐targeting TCR‐mimic antibodies (TCRm‐Abs) to enhance tumor‐specific NK cell‐mediated cytotoxicity. Using a high‐throughput hydrogel‐based microwell single‐cell chip (HMSC‐chip) coupled with T2 cell‐based de‐selection, we identified C33‐Ab, a functional TCRm‐Ab specific for p53 R175H /HLA‐A*02:01, from ∼500,000 hybridoma cells within 8 weeks. Based on this TCRm‐Ab, we constructed a bispecific NKCE (C33×CD16), a single‐chain diabody (scDb) linking C33‐Ab to an anti‐CD16 scFv. C33×CD16 specifically bridges NK cells with p53 R175H /HLA‐A*02:01‐positive cancer cells. It potently enhanced NK cell‐mediated cytotoxicity in vitro and antitumor efficacy in vivo upon adoptive NK‐cell transfer. This TCRm‐Ab‐based bispecific NKCE offers a promising strategy for tumor‐specific NK cell‐mediated immunotherapy by targeting intracellular oncogenic hotspot mutations.
- 13 May 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (6) , 1328-1342
High-throughput generation of patient-derived cancer stem cells for precision medicine using a microwell-chip platform
Substantial evidence indicates that cancer stem cells (CSCs) drive breast cancer (BRC) initiation, progression, therapy resistance, recurrence and metastasis. Evaluating drug efficacy against patient-derived CSCs can advance precision oncology. However, high-throughput isolation of functional CSCs from small clinical samples remains challenging. Tumoursphere formation, arising from the clonal expansion of a single cancer cell, is a standard in vitro method for CSC assay and enrichment. Here we show a microwell cell-chip culture platform that enables rapid, high-throughput generation of uniform micro-tumourspheres (MTSs) from limited BRC specimens, such as puncture biopsies, facilitating functional CSC enrichment and personalized drug testing within 8 days. Single-cell transcriptomics and limiting dilution tumour initiation assay confirm that MTSs recapitulate CSC functionality, uniformity and heterogeneity. MTSs predicted clinical outcomes in 16 patients with BRC with ~93.8% accuracy, underscoring their translational potential for personalized drug testing. Overall, this platform provides a robust tool for CSC-targeted precision medicine.
- 13 May 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (6) , 1328-1342
High-throughput generation of patient-derived cancer stem cells for precision medicine using a microwell-chip platform
Substantial evidence indicates that cancer stem cells (CSCs) drive breast cancer (BRC) initiation, progression, therapy resistance, recurrence and metastasis. Evaluating drug efficacy against patient-derived CSCs can advance precision oncology. However, high-throughput isolation of functional CSCs from small clinical samples remains challenging. Tumoursphere formation, arising from the clonal expansion of a single cancer cell, is a standard in vitro method for CSC assay and enrichment. Here we show a microwell cell-chip culture platform that enables rapid, high-throughput generation of uniform micro-tumourspheres (MTSs) from limited BRC specimens, such as puncture biopsies, facilitating functional CSC enrichment and personalized drug testing within 8 days. Single-cell transcriptomics and limiting dilution tumour initiation assay confirm that MTSs recapitulate CSC functionality, uniformity and heterogeneity. MTSs predicted clinical outcomes in 16 patients with BRC with ~93.8% accuracy, underscoring their translational potential for personalized drug testing. Overall, this platform provides a robust tool for CSC-targeted precision medicine.